Zikán M, Pinkavová I, Sláma J, Freitag P, Janousek M, Fischerová D, Pavlista D, Cibula D
Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha.
Ceska Gynekol. 2009 Dec;74(6):427-30.
To analyze up-to-data knowledge in the field of molecular characterization of epithelial ovarian borderline tumors with respect to clinical management and prognosis.
Review.
Oncogynecological Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine, and General Faculty Hospital, Prague.
Based on literature search and own experimental data in the field of molecular biology of ovarian cancer and borderline tumors of ovary, we summarize up-to-date knowledge of molecular differences and specific features of BTO with respect to implementation of these knowledge into the clinical management.
We suppose that spectrum of genomic changes (i.e. genetic and epigenetic) causing tumor transformation is limited and these changes take place in stem or progenitor cell. Analysis of genomic changes can help to define certain subtypes of BTO and, correlated to clinical characteristics, to identify subtypes with different biological behavior. Such molecular typing of BTO allows to individualize treatment.
分析上皮性卵巢交界性肿瘤分子特征领域中与临床管理和预后相关的最新知识。
综述。
布拉格查理大学医学院第一附属医院妇产科肿瘤妇科中心及布拉格综合医院。
基于卵巢癌和卵巢交界性肿瘤分子生物学领域的文献检索及自身实验数据，我们总结了关于交界性卵巢肿瘤（BTO）分子差异和特定特征的最新知识，以及将这些知识应用于临床管理的情况。
我们推测导致肿瘤转化的基因组变化（即遗传和表观遗传变化）范围有限，且这些变化发生在干细胞或祖细胞中。基因组变化分析有助于确定BTO的某些亚型，并与临床特征相关联，以识别具有不同生物学行为的亚型。这种BTO的分子分型有助于实现个体化治疗。
